274 related articles for article (PubMed ID: 30093449)
1. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
DuBois SG; Mosse YP; Fox E; Kudgus RA; Reid JM; McGovern R; Groshen S; Bagatell R; Maris JM; Twist CJ; Goldsmith K; Granger MM; Weiss B; Park JR; Macy ME; Cohn SL; Yanik G; Wagner LM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Boucher N; Czarnecki S; Luo C; Tsao-Wei D; Matthay KK; Marachelian A
Clin Cancer Res; 2018 Dec; 24(24):6142-6149. PubMed ID: 30093449
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
4. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kelly KR; Friedberg JW; Park SI; McDonagh K; Hayslip J; Persky D; Ruan J; Puvvada S; Rosen P; Iyer SP; Stefanovic A; Bernstein SH; Weitman S; Karnad A; Monohan G; VanderWalde A; Mena R; Schmelz M; Spier C; Groshen S; Venkatakrishnan K; Zhou X; Sheldon-Waniga E; Leonard EJ; Mahadevan D
Clin Cancer Res; 2018 Dec; 24(24):6150-6159. PubMed ID: 30082475
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
[TBL] [Abstract][Full Text] [Related]
6. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
Mody R; Yu AL; Naranjo A; Zhang FF; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Hank JA; Felder M; Birstler J; Sondel PM; Asgharzadeh S; Glade-Bender J; Katzenstein H; Maris JM; Park JR; Bagatell R
J Clin Oncol; 2020 Jul; 38(19):2160-2169. PubMed ID: 32343642
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.
Bagatell R; London WB; Wagner LM; Voss SD; Stewart CF; Maris JM; Kretschmar C; Cohn SL
J Clin Oncol; 2011 Jan; 29(2):208-13. PubMed ID: 21115869
[TBL] [Abstract][Full Text] [Related]
10. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
11. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.
Moreno L; Weston R; Owens C; Valteau-Couanet D; Gambart M; Castel V; Zwaan CM; Nysom K; Gerber N; Castellano A; Laureys G; Ladenstein R; Rössler J; Makin G; Murphy D; Morland B; Vaidya S; Thebaud E; van Eijkelenburg N; Tweddle DA; Barone G; Tandonnet J; Corradini N; Chastagner P; Paillard C; Bautista FJ; Gallego Melcon S; De Wilde B; Marshall L; Gray J; Burchill SA; Schleiermacher G; Chesler L; Peet A; Leach MO; McHugh K; Hayes R; Jerome N; Caron H; Laidler J; Fenwick N; Holt G; Moroz V; Kearns P; Gates S; Pearson ADJ; Wheatley K;
J Clin Oncol; 2024 Apr; 42(10):1135-1145. PubMed ID: 38190578
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
[TBL] [Abstract][Full Text] [Related]
14. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Falchook G; Coleman RL; Roszak A; Behbakht K; Matulonis U; Ray-Coquard I; Sawrycki P; Duska LR; Tew W; Ghamande S; Lesoin A; Schwartz PE; Buscema J; Fabbro M; Lortholary A; Goff B; Kurzrock R; Martin LP; Gray HJ; Fu S; Sheldon-Waniga E; Lin HM; Venkatakrishnan K; Zhou X; Leonard EJ; Schilder RJ
JAMA Oncol; 2019 Jan; 5(1):e183773. PubMed ID: 30347019
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK
J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
DuBois SG; Granger MM; Groshen S; Tsao-Wei D; Ji L; Shamirian A; Czarnecki S; Goodarzian F; Berkovich R; Shimada H; Villablanca JG; Vo KT; Pinto N; Mosse YP; Maris JM; Shusterman S; Cohn SL; Goldsmith KC; Weiss B; Yanik GA; Twist CJ; Irwin MS; Haas-Kogan DA; Park JR; Marachelian A; Matthay KK
J Clin Oncol; 2021 Nov; 39(31):3506-3514. PubMed ID: 34270348
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
Semrad TJ; Kim EJ; Gong IY; Li T; Christensen S; Arora M; Riess JW; Gandara DR; Kelly K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):335-341. PubMed ID: 33993383
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.
DuBois SG; Chesler L; Groshen S; Hawkins R; Goodarzian F; Shimada H; Yanik G; Tagen M; Stewart C; Mosse YP; Maris JM; Tsao-Wei D; Marachelian A; Villablanca JG; Matthay KK
Clin Cancer Res; 2012 May; 18(9):2679-86. PubMed ID: 22421195
[TBL] [Abstract][Full Text] [Related]
20. Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.
Graff JN; Higano CS; Hahn NM; Taylor MH; Zhang B; Zhou X; Venkatakrishnan K; Leonard EJ; Sarantopoulos J
Cancer; 2016 Aug; 122(16):2524-33. PubMed ID: 27192055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
